Jaguar Animal Health (JAGX) Stock Price, News & Analysis

Company Overview

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Key Stats

• Today's Range: $2.77 to $3.29
• 50-Day Range: $2.78 to $12.98
• 52-Week Range: $2.77 to $110.75
• Volume: 196,643 shs
• Average Volume: 51,525 shs
• Market Capitalization: $2.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Buy

Jaguar Animal Health Stock Analysis - MarketRank™

Jaguar Animal Health scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Jaguar Animal Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Jaguar Animal Health has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Jaguar Animal Health are expected to decrease in the coming year, from ($0.80) to ($2.06) per share.

Price to Book Value per Share Ratio

Jaguar Animal Health has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.74% of the float of Jaguar Animal Health has been sold short.

Short Interest Ratio / Days to Cover

Jaguar Animal Health has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Jaguar Animal Health has recently decreased by 10.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jaguar Animal Health does not currently pay a dividend.

Dividend Growth

Jaguar Animal Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.74% of the float of Jaguar Animal Health has been sold short.

Short Interest Ratio / Days to Cover

Jaguar Animal Health has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Jaguar Animal Health has recently decreased by 10.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for JAGX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Jaguar Animal Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jaguar Animal Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.38% of the stock of Jaguar Animal Health is held by insiders.

Percentage Held by Institutions

Only 12.04% of the stock of Jaguar Animal Health is held by institutions.

JAGX Stock Analysis - Frequently Asked Questions

How have JAGX shares performed this year?

Jaguar Animal Health's stock was trading at $25.25 at the beginning of the year. Since then, JAGX shares have decreased by 89.0% and is now trading at $2.78.
View the best growth stocks for 2025 here.

How were Jaguar Animal Health's earnings last quarter?

Jaguar Animal Health, Inc. (NASDAQ:JAGX) issued its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($16.70) earnings per share for the quarter, topping analysts' consensus estimates of ($18.50) by $1.80. The biotechnology company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $3.29 million. Jaguar Animal Health had a negative net margin of 343.92% and a negative trailing twelve-month return on equity of 432.91%.
Read the conference call transcript.

When did Jaguar Animal Health's stock split?

Shares of Jaguar Animal Health reverse split before market open on Thursday, May 23rd 2024. The 1-60 reverse split was announced on Thursday, May 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Jaguar Animal Health IPO?

Jaguar Animal Health (JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

How do I buy shares of Jaguar Animal Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Jaguar Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Jaguar Animal Health investors own include CrowdStrike (CRWD), NVIDIA (NVDA), Meta Platforms (META), Digital Turbine (APPS) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/20/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JAGX
• CIK: 1585608
• Web: www.jaguaranimalhealth.com
• Phone: (415) 371-8300
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $60.00
• High Stock Price Target: $60.00
• Low Stock Price Target: $60.00
• Potential Upside/Downside: +2,058.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.49 million
• Net Margins: -343.92%
• Pretax Margin: -350.41%
• Return on Equity: -432.91%
• Return on Assets: -71.25%

Debt

• Debt-to-Equity Ratio: 22.20
• Current Ratio: 1.08
• Quick Ratio: 0.70

Sales & Book Value

• Annual Sales: $11.69 million
• Price / Sales: 0.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.29 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 1,020,000
• Free Float: 1,014,000
• Market Cap: $2.84 million
• Optionable: No Data
• Beta: 0.68